Fluvirin Related Published Studies
Well-designed clinical trials related to Fluvirin (Influenza Virus Vaccine)
Intranasal vaccination with a replication-deficient influenza virus induces
heterosubtypic neutralising mucosal IgA antibodies in humans. [2014]
Safety of high dose trivalent inactivated influenza vaccine in pediatric patients
with acute lymphoblastic leukemia. [2014]
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A
H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. [2014]
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus
trivalent influenza vaccines in children aged 3-17 years. [2013]
Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine. [2012]
Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived
influenza vaccine in healthy children and adolescents three to seventeen years of
age. [2012]
A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. [2011.11.08]
Oil-in-water emulsion adjuvant with influenza vaccine in young children. [2011.10.13]
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. [2011.10.13]
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. [2011.10.13]
Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. [2011.09.15]
Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens. [2011.09]
Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. [2011.09]
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. [2011.09]
Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population. [2011.08]
Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. [2011.08]
A comparative study to evaluate the safety and immunogenicity of two lots of Haemophilus influenzae type-B conjugate vaccine manufactured at different scales. [2011.07.26]
Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. [2011.07.18]
Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. [2011.07.01]
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. [2011.07.01]
Increasing inner-city adult influenza vaccination rates: a randomized controlled trial. [2011.07]
Using implementation intentions prompts to enhance influenza vaccination rates. [2011.06.28]
Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. [2011.06.24]
Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. [2011.06.15]
Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. [2011.06.15]
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. [2011.06.01]
Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. [2011.06]
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. [2011.06]
Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. [2011.06]
Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. [2011.05.31]
A comparison of antibody responses to commercial equine influenza vaccines following annual booster vaccination of National Hunt horses - a randomised blind study. [2011.05.17]
A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. [2011.05.09]
Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. [2011.05]
Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. [2011.05]
Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. [2011.04.05]
Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. [2011.04]
Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. [2011.03.25]
Effects of selenium supplementation on selenoprotein gene expression and response to influenza vaccine challenge: a randomised controlled trial. [2011.03.21]
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. [2011.03.09]
Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. [2011.03.01]
Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. [2011.02.26]
Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country. [2011.02]
Cross-clade immunogenicity and safety of an AS03A-adjuvanted prepandemic H5N1 influenza vaccine in Hong Kong. [2011.02]
Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults. [2011.01.01]
Safety and immunogenicity of a new trivalent inactivated split-virus influenza
vaccine in healthy Korean children: a randomized, double-blinded,
active-controlled, phase III study. [2011]
Chloroquine for influenza prevention: a randomised, double-blind, placebo
controlled trial. [2011]
Trivalent inactivated influenza vaccine in African adults infected with human
immunodeficient virus: double blind, randomized clinical trial of efficacy,
immunogenicity, and safety. [2011]
A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. [2010.12]
A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. [2010.09.01]
Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. [2010.08.20]
Effects of a multi-faceted program to increase influenza vaccine uptake among health care workers in nursing homes: A cluster randomised controlled trial. [2010.07.12]
Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged >or=60 years). [2010.07.01]
Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? [2010.06.17]
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. [2010.06.07]
Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. [2010.06.01]
Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients. [2010.06]
Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. [2010.06]
The immunogenicity of intradermal influenza vaccination in COPD patients. [2010.05.28]
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. [2010.05.27]
Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. [2010.05.26]
Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. [2010.05.26]
Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. [2010.05.15]
Vaccination of ponies with the IE gene of EHV-1 in a recombinant modified live vaccinia vector protects against clinical and virological disease. [2010.05.15]
Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. [2010.04.12]
A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. [2010.04.01]
[Safety and immunogenicity of the diphtheria, tetanus, accellular pertussis plus hemophilus influenza type b combined vaccine (DTaP-Hib) to Chinese infants] [2010.04]
Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. [2010.04]
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. [2010.03.17]
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. [2010.03.16]
Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. [2010.03.10]
Comparative effectiveness of two pharmacy-based colorectal cancer screening interventions during an annual influenza vaccination campaign. [2010.03.01]
Protection and differentiation of infected from vaccinated animals by an inactivated recombinant Newcastle disease virus/avian influenza H5 vaccine. [2010.03]
Improving influenza vaccination rates in the workplace: a randomized trial. [2010.03]
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. [2010.02.17]
Mask use, hand hygiene, and seasonal influenza-like illness among young adults: a randomized intervention trial. [2010.02.15]
Impact of influenza-like illness and effectiveness of influenza vaccination in oncohematological children who have completed cancer therapy. [2010.02.10]
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. [2010.02.10]
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. [2010.02.01]
Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. [2010.02]
Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia. [2010.01.22]
Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. [2010.01.06]
Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. [2010.01.02]
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. [2010.01.02]
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. [2010.01.02]
Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly. [2010]
Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. [2010]
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. [2010]
Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled,
randomized, double-blind crossover study. [2010]
Immunogenicity, large scale safety and lot consistency of an intradermal
influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III
trial. [2010]
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in
healthy adults: a randomized, placebo-controlled trial over two influenza
seasons. [2010]
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid
DNA vaccines encoding influenza A virus H5 hemagglutinin. [2010]
A novel type of influenza vaccine: safety and immunogenicity of
replication-deficient influenza virus created by deletion of the interferon
antagonist NS1. [2010]
Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. [2009.12.30]
Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial. [2009.12]
Efficacy of a replikin peptide vaccine against low-pathogenicity avian influenza H5 virus. [2009.12]
Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. [2009.09]
Well-designed clinical trials possibly related to Fluvirin (Influenza Virus Vaccine)
Clinical effects of probiotic Bifidobacterium longum BB536 on immune function and
intestinal microbiota in elderly patients receiving enteral tube feeding. [2013]
Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. [2011.08.15]
The effectiveness of the FLU-FOBT program in primary care a randomized trial. [2011.07]
Using the Health Action Process Approach and implementation intentions to increase flu vaccine uptake in high risk Thai individuals: a controlled before-after trial. [2011.07]
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. [2011.06.16]
|
